Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. (OTLK) reported that Nasdaq notified the company on June 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after the closing bid price of its common stock met or exceeded $1.00 for ten consecutive business days. The company had previously received a delisting notice on February 18, 2026 for failing to maintain the $1.00 minimum bid price. Outlook’s common stock is $0.01 par value.

Key Details

• Nasdaq initially notified Outlook of a delisting determination on February 18, 2026 for failing to meet the $1.00 minimum bid requirement under Rule 5550(a)(2).
• Between June 11–June 25, 2026 the closing bid price was $1.00 or greater for ten consecutive business days.
• On June 26, 2026 Nasdaq informed the company that the matter is now closed and the company has regained compliance.
• The action preserves listing on the Nasdaq Capital Market for now; continued compliance depends on maintaining listing standards.

Why It Matters
Regaining compliance removes the immediate risk of delisting, meaning Outlook’s shares remain listed on the Nasdaq Capital Market, which supports liquidity and visibility for investors. However, the company must continue to meet Nasdaq’s minimum bid-price requirement going forward; failure to do so could result in renewed delisting proceedings. Investors should monitor the company’s share price and any future Nasdaq correspondence for changes in listing status.